Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors

- Smith, Amanda M., Dun, Matthew D., Toop, Hamish, Lock, Richard B., Powell, Jason A., Thomas, Daniel, Guthridge, Mark A., Moore, Andrew, Ashman, Leonie K., Skelding, Kathryn A., Enjeti, Anoop, Verrills, Nicole M., Lee, Erwin M., Harrison, Celeste, Kahl, Richard, Flanagan, Hayley, Panicker, Nikita, Mashkani, Baratali, Don, Anthony S., Morris, Jonathan

FMS-like tyrosine kinase 3 (FLT3) inhibitors: molecular docking and experimental studies

- Mashkani, Baratali, Tanipour, Mohammad Hossein, Saadatmandzadeh, Mohammad, Ashman, Leonie K., Griffith, Renate

Differences in growth promotion, drug response and intracellular protein trafficking of FLT3 mutants

- Mashkani, Baratali, Griffith, Renate, Ashman, Leonie

Expression of biologically active human colony stimulating factor-1 in Pichia pastoris

- Mashkani, Baratali, Odell, Adam F., Byrnes, Ellen M., Griffith, Renate, Ashman, Leonie K.

MicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and interacts with Pim-1

- Kim, Kyu-Tae, Carroll, Adam P., Mashkani, Baratali, Cairns, Murray J., Small, Donald, Scott, Rodney J.

Colony stimulating factor-1 receptor as a target for small molecule inhibitors

- Mashkani, Baratali, Griffith, Renate, Ashman, Leonie K.

Hybrid promoters directed tBid gene expression to breast cancer cells by transcriptional targeting

- Farokhimanesh, Samila, Rahbarizadeh, Fatemah, Rasaee, Mohammad J., Kamali, Abbas, Mashkani, Baratali

Small molecule inhibitors for type III receptor tyrosine kinases

- Mashkani, Baratali